1887

Journal of General Virology header logo

Volume 91, Issue 7

Convalescent phase sera from children infected with G12 rotavirus cross-neutralize rotavirus strains belonging to the Wa genogroup Free

Abstract

The emergence of G12 rotaviruses raises questions about the ability of candidate vaccines in providing protection against such emerging genotypes. Therefore, we assessed cross-neutralization against four reference rotavirus strains namely Wa (G1P[8]), DS-1 (G2P[4]), 116E (G9P[11]) and RV024 (G12P[6]) using paired sera from 28 children infected with G1P[8], G2P[4], G9P[6/8] or G12P[6] genotypes. Convalescent sera of G12P[6]-infected children demonstrated heterotypic response against 116E and Wa strains (50 and 33.3 %). In contrast, none of the four G2P[4]-infected children seroconverted against Wa or RV024 rotaviruses. The geometric mean neutralizing antibody titre in convalescent sera of G12P[6]-infected children was eightfold higher against strains belonging to the Wa genogroup (i.e. G1, G9 and G12 rotavirus) than against strains belonging to the DS-1 genogroup (G2 rotavirus). In conclusion, this study demonstrates that neutralization in part may be genogroup specific, and thus a monovalent vaccine based on the Wa genogroup is likely to protect against the G12 rotaviruses.

  • Received:
  • Accepted:
  • Published Online:
© SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.019489-0
2010-07-01
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/91/7/1794.html?itemId=/content/journal/jgv/10.1099/vir.0.019489-0&mimeType=html&fmt=ahah

References

  1. Arias, C. F., Lopez, S., Mascarenhas, J. D., Romero, P., Cano, P., Gabbay, Y. B., de Freitas, R. B. & Linhares, A. C.(1994). Neutralizing antibody immune response in children with primary and secondary rotavirus infections. Clin Diagn Lab Immunol 1, 89–94. [Google Scholar]
  2. Bahl, R., Ray, P., Subodh, S., Shambharkar, P., Saxena, M., Parashar, U., Gentsch, J., Glass, R. & Bhan, M. K.(2005). Incidence of severe rotavirus diarrhea in New Delhi, India, and G and P types of the infecting rotavirus strains. J Infect Dis 192, S114–S119.[CrossRef] [Google Scholar]
  3. Bernstein, D. I., Sack, D. A., Rothstein, E., Reisinger, K., Smith, V. E., O’Sullivan, D., Spriggs, D. R. & Ward, R. L.(1999). Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomised placebo-controlled trial. Lancet 354, 287–290.[CrossRef] [Google Scholar]
  4. Bhan, M. K., Lew, J. F., Sazawal, S., Das, B. K., Gentsch, J. R. & Glass, R. I.(1993). Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 168, 282–287.[CrossRef] [Google Scholar]
  5. Bhandari, N., Sharma, P., Glass, R. I., Ray, P., Greenberg, H., Taneja, S., Saksena, M., Rao, C. D., Gentsch, J. R. & other authors(2006). Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine 24, 5817–5823.[CrossRef] [Google Scholar]
  6. Bhandari, N., Sharma, P., Taneja, S., Kumar, T., Rongsen-Chandola, T., Appaiahgari, M. B., Mishra, A., Singh, S. & Vrati, S.(2009). A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis 200, 421–429.[CrossRef] [Google Scholar]
  7. Brüssow, H., Clark, H. F. & Sidoti, J.(1991). Prevalence of serum neutralizing antibody to serotype 9 rotavirus WI61 in children from South America and central. J Clin Microbiol 29, 208–211. [Google Scholar]
  8. Choi, A. H., McNeal, M. M., Basu, M., Flint, J. A., Stone, S. C., Clements, J. D., Bean, J. A., Poe, S. A., VanCott, J. L. & Ward, R. L.(2002). Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine 20, 3310–3321.[CrossRef] [Google Scholar]
  9. Das, B. K., Gentsch, J. R., Cicirello, H. G., Woods, P. A., Gupta, A., Ramachandran, M., Kumar, R., Bhan, M. K. & Glass, R. I.(1994). Characterization of rotavirus strains from newborns in New Delhi, India. J Clin Microbiol 32, 1820–1822. [Google Scholar]
  10. Glass, R. I., Bhan, M. K., Ray, P., Bahl, R., Parashar, U. D., Greenberg, H., Rao, C. D., Bhandari, N., Maldonado, Y. & other authors(2005). Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 192, S30–S35.[CrossRef] [Google Scholar]
  11. Glass, R. I., Parashar, U. D., Bresee, J. S., Turcios, R., Fischer, T. K., Widdowson, M., Jiang, B. & Gentsch, J. R.(2006). Rotavirus vaccines: current prospects and future challenges. Lancet 368, 323–332.[CrossRef] [Google Scholar]
  12. Heaton, P. M., Goveia, M. G., Miller, J. M., Offit, P. & Clark, H. F.(2005). Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 192, S17–S21.[CrossRef] [Google Scholar]
  13. Hoshino, Y. & Kapikian, A. Z.(1996). Classification of rotavirus VP4 and VP7 serotypes. Arch Virol Suppl 12, 99–111. [Google Scholar]
  14. Hoshino, Y., Sereno, M. M., Midthun, K., Flores, J., Kapikian, A. Z. & Chanock, R. M.(1985). Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity. Proc Natl Acad Sci U S A 82, 8701–8704.[CrossRef] [Google Scholar]
  15. Jiang, B., Gentsch, J. R. & Glass, R. I.(2008). Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 26, 6754–6758.[CrossRef] [Google Scholar]
  16. Kirkwood, C. D. & Buttery, J.(2003). Rotavirus vaccines – an update. Expert Opin Biol Ther 3, 97–105.[CrossRef] [Google Scholar]
  17. Knowlton, D. R., Spector, D. M. & Ward, R. L.(1991). Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods 33, 127–134.[CrossRef] [Google Scholar]
  18. Kutsuzawa, T., Konno, T., Suzuki, H., Kapikian, A. Z., Ebina, T. & Ishida, N.(1982). Isolation of human rotavirus subgroups 1 and 2 in cell culture. J Clin Microbiol 16, 727–730. [Google Scholar]
  19. Malik, J., Bhan, M. K. & Ray, P.(2008). Natural immunity to rotavirus infection in children. Indian J Biochem Biophys 45, 219–228. [Google Scholar]
  20. Matthijnssens, J., Ciarlet, M., Heiman, E., Arijs, I., Delbeke, T., McDonald, S. M., Palombo, E. A., Iturriza-Gómara, M., Maes, P. & other authors(2008). Full genome-based classification of rotaviruses reveals a common origin between human Wa-like and porcine rotavirus strains and human DS-1-like and bovine rotavirus strains. J Virol 82, 3204–3219.[CrossRef] [Google Scholar]
  21. Offit, P. A. & Blavat, G.(1986). Identification of the two rotavirus genes determining neutralization specificities. J Virol 57, 376–378. [Google Scholar]
  22. Parashar, U. D., Gibson, C. J., Bresse, J. S. & Glass, R. I.(2006). Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12, 304–306.[CrossRef] [Google Scholar]
  23. Rahman, M., Matthijnssens, J., Yang, X., Delbeke, T., Arijs, I., Taniguchi, K., Iturriza-Gomara, M., Iftekharuddin, N., Azim, T. & Van Ranst, M.(2007). Evolutionary history and global spread of the emerging G12 human rotaviruses. J Virol 81, 2382–2390.[CrossRef] [Google Scholar]
  24. Ramachandran, M., Vij, A., Kumar, R., Das, B. K., Gentsch, J. R., Bhan, M. K. & Glass, R. I.(1998). Lack of maternal antibodies to P serotypes may predispose neonates to infections with unusual rotavirus strains. Clin Diagn Lab Immunol 5, 527–530. [Google Scholar]
  25. Ray, P. G. & Kelkar, S. D.(2004). Prevalence of neutralizing antibodies against different rotavirus serotypes in children with severe rotavirus-induced diarrhea and their mothers. Clin Diagn Lab Immunol 11, 186–194. [Google Scholar]
  26. Ray, P., Sharma, S., Agarwal, R. K., Longmei, K., Gentsch, J. R., Paul, V. K., Glass, R. I. & Bhan, M. K.(2007). First detection of G12 rotaviruses in newborns with neonatal rotavirus infection at All India Institute of Medical Sciences, New Delhi, India. J Clin Microbiol 45, 3824–3827.[CrossRef] [Google Scholar]
  27. Ruiz-Palacios, G. M., Perez-Schael, I., Velazquez, F. R., Abate, H., Breuer, T., Clemens, S. C., Cheuvart, B., Espinoza, F., Gillard, P. & other authors(2006). Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354, 11–22.[CrossRef] [Google Scholar]
  28. Santos, N. & Hoshino, Y.(2005). Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15, 29–56.[CrossRef] [Google Scholar]
  29. Schumann, T., Hotzel, H., Otto, P. & Johne, R.(2009). Evidence of interspecies transmission and reassortment among avian group A rotaviruses. Virology 386, 334–343.[CrossRef] [Google Scholar]
  30. Sharma, S., Ray, P., Gentsch, J. R., Glass, R. I., Kalra, V. & Bhan, M. K.(2008). Emergence of G12 rotavirus strains in Delhi, India, in 2000 to 2007. J Clin Microbiol 46, 1343–1348.[CrossRef] [Google Scholar]
  31. Sharma, S., Paul, V. K., Bhan, M. K. & Ray, P.(2009). Genomic characterization of nontypeable rotaviruses and detection of a rare G8 strain from Delhi, India. J Clin Microbiol 47, 3998–4005.[CrossRef] [Google Scholar]
  32. Uchida, R., Pandey, B. D., Sherchand, J. B., Ahmed, K., Yokoo, M., Nakagomi, T., Cuevas, L. E., Cunliffe, N. A., Hart, C. A. & Nakagomi, O.(2006). Molecular epidemiology of rotavirus diarrhea among children and adults in Nepal: detection of G12 strains with P[6] or P[8] and a G11P[25] strain. J Clin Microbiol 44, 3499–3505.[CrossRef] [Google Scholar]
  33. Ursu, K., Kisfali, P., Rigo, D., Ivanics, E., Erdelyi, K., Dan, A., Melegh, B., Martella, V. & Banyai, K.(2009). Molecular analysis of the VP7 gene of pheasant rotaviruses identifies a new genotype, designated G23. Arch Virol 154, 1365–1369.[CrossRef] [Google Scholar]
  34. Vesikari, T., Matson, D. O., Dennehy, P., Van Damme, P., Santosham, M., Rodriguez, Z., Dallas, M. J., Heyse, J. F., Goveia, M. G. & other authors(2006). Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354, 23–33.[CrossRef] [Google Scholar]
  35. Ward, R. L., Sander, D. S., Schiff, G. M. & Bernstein, D. I.(1990). Effect of vaccination on serotype-specific antibody responses in infants administered WC3 bovine rotavirus before or after a natural rotavirus infection. J Infect Dis 162, 1298–1303.[CrossRef] [Google Scholar]
  36. Yu, J. & Langridge, W. H.(2001). A plant-based multicomponent vaccine protects mice from enteric diseases. Nat Biotechnol 19, 548–552.[CrossRef] [Google Scholar]
  37. Zheng, B. J., Han, S. X., Yan, Y. K., Liang, X. R., Ma, G. Z., Yang, Y. & Ng, M. H.(1988). Development of neutralizing antibodies and group A common antibodies against natural infections with human rotavirus. J Clin Microbiol 26, 1506–1512. [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.019489-0
Loading
Convalescent phase sera from children infected with G12 rotavirus cross-neutralize rotavirus strains belonging to the Wa genogroup
J. Gen. Virol. 91, 1794 (2010); https://doi.org/10.1099/vir.0.019489-0
/content/journal/jgv/10.1099/vir.0.019489-0
/content/journal/jgv/10.1099/vir.0.019489-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error